Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus platinum-based chemotherapy in advanced lung cancer
CTR20170361Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in bronchial carcinoma, non-small cell lung cancer (NSCLC), Non-small cell lung cancer (NS-NSCLC), Pulmonary squamous cell carcinoma, small cell lung cancer (SCLC), sponsored by BeiGene. Started Jul 2017; status: completed.
02
Drugs
tislelizumab
03
Conditions
bronchial carcinomanon-small cell lung cancer (NSCLC)Non-small cell lung cancer (NS-NSCLC)Pulmonary squamous cell carcinomasmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20170361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170361.